QARZIBA 4.5mg/ml concentrate for solution for infusion EUSA PHARMA ORIGINAL MEDICINE
Chemical substance: dinutuximab beta
Active substance
Results for the substance dinutuximab beta
1 result
About this active substance
Dinutuximab beta is a monoclonal antibody used for the treatment of high-risk neuroblastoma in children. It works by binding to the GD2 antigen on tumor cell surfaces, stimulating the immune system to destroy cancer cells.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include pain, fever, allergic reactions, hypotension, or hematologic toxicity. In rare cases, anaphylactic reactions or tumor lysis syndrome may occur.
Dinutuximab beta is not recommended for patients with hypersensitivity to this medication or severe conditions compromising immune function.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include pain, fever, allergic reactions, hypotension, or hematologic toxicity. In rare cases, anaphylactic reactions or tumor lysis syndrome may occur.
Dinutuximab beta is not recommended for patients with hypersensitivity to this medication or severe conditions compromising immune function.